MORE Health Launches Coronavirus COVID-19 Self-Assessment

Food and Healthcare Press Releases Wednesday March 25, 2020 08:40
SAN MATEO California--25 Mar--PRNewswire/InfoQuest

On March 24, 2020, MORE Health, a Silicon Valley headquartered cross-border telemedicine company, is launching a premier, freely available self-assessment tool for COVID-19 in six languages at covid19.morehealth.com.

The MORE COVID-19 Self-Assessment was co-developed by a team of U.S. and international infectious disease experts, including Dr. Gary Schoolnik, former Chief of Infectious Diseases at Stanford Hospital and Professor of Medicine at Stanford University, and Professor Wang Yan, Deputy Director of the Department of Infectious Diseases at Peking University First Hospital. Dr. Schoolnik has long been devoted to the research and treatment of infectious disease in the U.S. and around the world. And he is currently treating COVID-19 patients in the United States. Professor Wang Yang has specialized in the practice of clinical infectious disease for over 20 years, and she has direct experience treating patients with COVID-19 and remotely assisting medical staff in Wuhan, Hubei with severe COVID-19 infections.

The self-assessment can help guide a user to decide if they should recuperate at home or drive to a designated testing location; it can help users decide if they should call 911 or contact their primary care physician for help. MORE Health's tool can reduce anxiety and panic in the majority of people for whom testing is not needed, and can also screen people who are possibly infected in large numbers simultaneously reducing the burden on healthcare systems and helping to quickly identify high-risk patients.

To broaden access, MORE Health is making self-assessment completely free to users and hospitals around the world to help them customize their own hierarchical diagnosis and treatment system. The website does not have advertisements and it does not collect any personal information.

About MORE Health

Long before the outbreak began, MORE Health was assisting Chinese physicians by allowing them to use our platform to consult with top physicians at top US hospitals.   Over time MORE Health perfected its platform through practical experience with cases and technological refinements. MORE Health is now a leader in the field of cross-border telemedicine. It also has strong capabilities in artificial intelligence-supported diagnosis, and it has developed artificial intelligence diagnostic programs for patients with lung cancer. Learn more at www.morehealth.com, or contact them at hello@morehealth.com.

Logo - https://mma.prnewswire.com/media/596627/MORE_Health_Logo.jpg

Latest Press Release

Ansell Urges Global Priority For Supply Of Personal Protective Equipment

Ansell Limited, a global leader in protective solutions, is working with governments and health organizations worldwide to ensure unrestricted personal protective equipment (PPE) manufacture and supply is given top priority during the COVID-19...

Yiling Pharmacy Lianhua Qingwen has been approved by the Thai FDA

On March 31, Shijiazhuang Yiling Pharmaceutical Co., Ltd released a notice that they had received the approval of the modern herbal medicine registration issued by the Food and Drug Administration of Thailand. Lianhua Qingwen Capsule is recognized as in...

EW Nutrition Launches Industry-leading Webinar Series With Topical Antimicrobial Resistance Twin Sessions

Yesterday, German-based company EW Nutrition took a first step toward serving the animal production industry in these challenging times. The in-feed and on-farm solutions company has started a series of topical webinars on challenging issues such as...

Saxenda(R) Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda(R) (liraglutide 3.0 mg) in adolescents (aged 12–<18) with obesity.1 The study was accepted...

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson...

Related Topics